SCHEMBL6355564

SCHEMBL6355564

O=C1Nc2ccc(C(=O)CCl)cc2/C1=C1\C=Cc2ccccc2N1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NEK2 P51955 4/20 0.48
CDK1 P06493 3/20 0.48
CCNB1 P14635 3/20 0.48
RAF1 P04049 1/20 0.45
ALDH1A1 P00352 3/20 0.37
MAPT P10636 2/20 0.37
TLK2 Q86UE8 5/20 0.35
TRPA1 O75762 1/20 0.35
MAPK1 P28482 1/20 0.35
GSK3B P49841 1/20 0.35
HIF1A Q16665 1/20 0.35
GAA P10253 1/20 0.34
KDM4E B2RXH2 1/20 0.34
SMYD3 Q9H7B4 1/20 0.33
MAP3K7 O43318 1/20 0.33
TAB1 Q15750 1/20 0.33
CHEK1 O14757 1/20 0.33
PIM1 P11309 1/20 0.33
PAK4 O96013 1/20 0.32
PDPK1 O15530 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6355565 1.00 NEK2 (0.48) NEK2CDK1CCNB1RAF1ALDH1A1
SCHEMBL6354459 0.90 NEK2 (0.39) NEK2CDK1CCNB1RAF1MAPT
SCHEMBL6354458 0.90 NEK2 (0.39) NEK2CDK1CCNB1RAF1MAPT
SCHEMBL6351562 0.85 TLK2 (0.44) CDK1CCNB1MAPTTLK2GSK3B
SCHEMBL6351566 0.85 TLK2 (0.44) CDK1CCNB1MAPTTLK2GSK3B
SCHEMBL6355562 0.85 TLK2 (0.38) NEK2CDK1CCNB1RAF1ALDH1A1
SCHEMBL6355557 0.85 TLK2 (0.38) NEK2CDK1CCNB1RAF1ALDH1A1
SCHEMBL6355400 0.80 PDPK1 (0.38) CDK1CCNB1RAF1ALDH1A1MAPT
SCHEMBL6351020 0.79 NTRK1 (0.46) MAPTGAAMAP3K7TAB1CHEK1
SCHEMBL6351016 0.79 NTRK1 (0.46) MAPTGAAMAP3K7TAB1CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050090498-A1 3-Quinolin-2(1h)-ylideneindolin-2-one derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-04-28 US disclosed
EP-1396490-A1 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2004-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090498-A1 3-Quinolin-2(1h)-ylideneindolin-2-one derivative KDR, FLT4, FLT1 NEK2 1970/4885CDK1 1166/4885CCNB1 2204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.